Druggable cancer phosphatases
- 7 April 2021
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (588)
- https://doi.org/10.1126/scitranslmed.abe2967
Abstract
The phosphorylation status of oncoproteins is regulated by both kinases and phosphatases. Kinase inhibitors are rarely sufficient for successful cancer treatment, and phosphatases have been considered undruggable targets for cancer drug development. However, innovative pharmacological approaches for targeting phosphatases have recently emerged. Here, we review progress in the therapeutic targeting of oncogenic Src homology region 2 domain-containing phosphatase-2 (SHP2) and tumor suppressor protein phosphatase 2A (PP2A) and select other druggable oncogenic and tumor suppressor phosphatases. We describe the modes of action for currently available small molecules that target phosphatases, their use in drug combinations, and advances in clinical development toward future cancer therapies.Keywords
Funding Information
- Breast Cancer Now (2017NovPCC1067)
- Foundation of the Finnish Cancer Institute
This publication has 116 references indexed in Scilit:
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cellsJCI Insight, 2013
- Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A‐RIPK1‐dependent necroptosisEMBO Molecular Medicine, 2012
- CIP2A Promotes Proliferation of Spermatogonial Progenitor Cells and Spermatogenesis in MicePLOS ONE, 2012
- A large-scale method to measure absolute protein phosphorylation stoichiometriesNature Methods, 2011
- Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)Journal of Medicinal Chemistry, 2010
- Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineagesNature Chemical Biology, 2009
- PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2A–Mediated Inactivation in Human Malignant GliomaCancer Research, 2009
- From Promiscuity to Precision: Protein Phosphatases Get a MakeoverMolecular Cell, 2009
- FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemiaJCI Insight, 2007
- NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTENCell, 2007